Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,538 | -20.7% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 1,940 | -23.0% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 2,518 | -62.1% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 6,652 | +32.1% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 5,034 | +92.3% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 2,618 | +115.7% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 1,214 | +5.7% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 1,148 | +287.8% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 296 | – | SEC Filing (0001104659-18-003691) ↗ |
Breakdown
What makes up rapid diagnostics (legacy standalone subsegment through fy2025q4 — id now, binaxnow, panbio) — u.s. revenue ($m)
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — U.S. Revenue ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-rev-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.